Serving 500+ biopharmaceutical companies globally:
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
Serving 500+ biopharmaceutical companies globally:
Generated: September 20, 2017
What is the competitive landscape for SUN PHARM INDS, and when can generic versions of SUN PHARM INDS drugs launch?
SUN PHARM INDS has three hundred and seventy-eight approved drugs.| Patents: | 14 |
| Tradenames: | 227 |
| Ingredients: | 213 |
| NDAs: | 378 |
Export unavailable in trial.
Subscribe for complete access.
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sun Pharm Inds | BACTRIM | sulfamethoxazole; trimethoprim | SUSPENSION;ORAL | 017560-001 | Approved Prior to Jan 1, 1982 | ► Subscribe | ► Subscribe | ||||||||||||||||||||||
Sun Pharm Inds Inc | EXELDERM | sulconazole nitrate | SOLUTION;TOPICAL | 018738-001 | Aug 30, 1985 | ► Subscribe | ► Subscribe | ||||||||||||||||||||||
Sun Pharm Inds | BACTRIM DS | sulfamethoxazole; trimethoprim | TABLET;ORAL | 017377-002 | Approved Prior to Jan 1, 1982 | ► Subscribe | ► Subscribe | ||||||||||||||||||||||
Sun Pharm Inds | BACTRIM | sulfamethoxazole; trimethoprim | TABLET;ORAL | 017377-001 | Approved Prior to Jan 1, 1982 | ► Subscribe | ► Subscribe | ||||||||||||||||||||||
Sun Pharm Inds | BACTRIM PEDIATRIC | sulfamethoxazole; trimethoprim | SUSPENSION;ORAL | 017560-002 | Approved Prior to Jan 1, 1982 | ► Subscribe | ► Subscribe | ||||||||||||||||||||||
Sun Pharm Inds Ltd | ULTRAVATE | halobetasol propionate | CREAM;TOPICAL | 019967-001 | Dec 27, 1990 | ► Subscribe | ► Subscribe | ||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
isotretinoin | Capsules | 25 mg | ABSORICA | 5/16/2016 |
isotretinoin | Capsules | 35 mg | ABSORICA | 11/25/2015 |
isotretinoin | Capsules | 20 mg | ABSORICA | 6/19/2013 |
isotretinoin | Capsules | 20 mg | ABSORICA | 1/7/2013 |
isotretinoin | Capsules | 30 mg and 40 mg | ABSORICA | 12/31/2012 |
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6,559,187 | Liquid formulation of metformin | ► Subscribe | |||||||||||||||||||||||||||
| 9,192,615 | Method for the treatment of acne and certain dosage forms thereof | ► Subscribe | |||||||||||||||||||||||||||
| 8,722,650 | Extended-release minocycline dosage forms | ► Subscribe | |||||||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
| Country | Document Number | Estimated Expiration | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Slovakia | 2102003 | ► Subscribe | |||||||||||||||||||||||||||
| Mexico | PA03001157 | ► Subscribe | |||||||||||||||||||||||||||
| Israel | 154307 | ► Subscribe | |||||||||||||||||||||||||||
| World Intellectual Property Organization (WIPO) | 2010017310 | ► Subscribe | |||||||||||||||||||||||||||
| World Intellectual Property Organization (WIPO) | 2015094574 | ► Subscribe | |||||||||||||||||||||||||||
| Canada | 2888853 | ► Subscribe | |||||||||||||||||||||||||||
| Japan | 5744976 | ► Subscribe | |||||||||||||||||||||||||||
| Japan | 2004505913 | ► Subscribe | |||||||||||||||||||||||||||
| Hong Kong | 1214154 | ► Subscribe | |||||||||||||||||||||||||||
| Eurasian Patent Organization | 201590730 | ► Subscribe | |||||||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws,
it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description | ||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0677 | Netherlands | ► Subscribe | PRODUCT NAME: COMBINATIE VAN DAPAGLIFLOZINE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN EN METFORMINE OF EEN FARMACEITISCH AANVAARDBAAR ZOUT DAARVAN, ZOALS BESCHERMD DOOR HET BASISOCTROOI EP 1506211B1; REGISTRATION NO/DATE: EU/1/13/900 20140121 | ||||||||||||||||||||||||||
| 2015000093 | Germany | ► Subscribe | PRODUCT NAME: LEVONORGESTREL UND ETHINYLESTRADIOL; NAT. REGISTRATION NO/DATE: 87675.00.00 20150720; FIRST REGISTRATION: SLOWAKEI 17/0017/15-S 20150129 | ||||||||||||||||||||||||||
| 00152 | Netherlands | ► Subscribe | PRODUCT NAME: TRAMADOLI HYDROCHLORIDUM EN PARACETAMOLUM; NAT. REGISTRATION NO/DATE: RVG 28113 20030115; FIRST REGISTRATION: 359 228-3 2002050405 | ||||||||||||||||||||||||||
| C0028 | France | ► Subscribe | PRODUCT NAME: ASSOCIATION COMPRENANT LA SAXAGLIPTINE OU UN DE SES SELS ET LA METFORMINE OU UN DE SES SELS, Y COMPRIS L'ASSOCIATION CHLORHYDRATE DE SAXAGLIPTINE ET CHLORHYDRATE DE METFORMINE; REGISTRATION NO/DATE: EU/1/11/731/001 20111124 | ||||||||||||||||||||||||||
| C/GB96/053 | United Kingdom | ► Subscribe | PRODUCT NAME: DOXORUBICIN SULPHATE; REGISTERED: UK EU/1/96/011/001 19960621; UK EU/1/96/011/002 19960621 | ||||||||||||||||||||||||||
| 90013-1 | Sweden | ► Subscribe | PRODUCT NAME: NAPROXEN OCH ESOMEPRAZOL; NAT. REG. NO/DATE: MTNR 43248 20101203; FIRST REG.: GB PL 17901/0263 20101105 | ||||||||||||||||||||||||||
| 2014 00037 | Denmark | ► Subscribe | PRODUCT NAME: ET KOMBINATIONSPRODUKT AF DAPAGLIFLOZIN ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, HERUNDER DAPAGLIFLOZINPROPANDIOLMONOHYDRAT OG METFORMIN ELLER SALTE DERAF, HERUNDER METFORMINHYDROCHLORID; REG. NO/DATE: EU/1/13/900 20140116 | ||||||||||||||||||||||||||
| 90002 | Netherlands | ► Subscribe | PRODUCT NAME: CLOPIDOGREL WATERSTOFSULFAAT; REGISTRATION NO/DATE: EU 1/98/069/001 - EU 1/98/069/003 19980715 | ||||||||||||||||||||||||||
| C0008 | Belgium | ► Subscribe | PRODUCT NAME: RISPERIDONE; NAT REG.: 2 S 414 F 3 19940527; FIRST REG.: GB 0242/0186 19921208 | ||||||||||||||||||||||||||
| 2011005,C0984957 | Lithuania | ► Subscribe | PRODUCT NAME: NAPROXENUM + ESOMEPRAZOLUM; REGISTRATION NO/DATE: LT/1/10/2302/001-LT/1/10/2302/012 20110126 | ||||||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
Serving 500+ biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Follow DrugPatentWatch:
Join the 22,707 others who get our Drug Patent Expiration Alerts:
